Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia

International Clinical Psychopharmacology

Volumn 14, Issue 6, 1999, Pages 345-351

  DeVane, C Lindsay ^a   Ware, Michael R ^a   Emmanuel, Naresh P ^a   Brawman Mintzer, Olga ^a   Morton, W Alexander ^a   Villarreal, Gerardo ^a   Lydiard, R Bruce ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Fluvoxamine; Pharmacotherapy; Social phobia

Indexed keywords

FLUVOXAMINE; HYDROCORTISONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SOCIAL PHOBIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PRESSURE; FEMALE; FLUVOXAMINE; HEART RATE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SINGLE-BLIND METHOD;

EID: 0032709316     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199911000-00004     Document Type: Article

References (37)

1. Beck M (1995) Fluoxetine and social phobia. J Clin Psychiatry 56:36-37.
2. Beidel DC, Turner SM, Jacob RG (1989) Assessment of social phobia: Reliability of an impromptu speech task. J Anxiety Dis 3:149-158.
3. Black B, Uhde TW, Tancer ME (1992) Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 12:293-295.
4. Czepowicz VD, Johnson MR, Lydiard RB, Emmanuel NP, Ware MR, Mintzer OB, et al. (1995) Sertraline in social phobia. J Clin Psychopharmacol 15:372-373.
5. Den Boer JA, Van Vliet IM, Westenberg HGM (1994) Recent advances in the psychopharmacology of social phobia. Prog Neuro-Psychopharmacol Biol Psychiatry 18:625-645.
6. Davidson JRT, Potts NLS, Richichi EA, Ford SM, Krishna KRR, Smith RD, Wilson W. (1991) The brief social phobia scale. J Clin Psychiatry 52 (Suppl 11):48-51.
7. DeVane CL (1997) The place of selective serotonin reuptake inhibitors in the treatment of panic disorder. Pharmacotherapy 17:282-292.
8. DeVane CL, Gill HS (1997) Clinical pharmacokinetics of fluvoxamine: Applications to dosage regimen design. J Clin Psychiatry 58 (Suppl 5):7-14.
9. Gelernter CS, Udhe TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 48:938-45.
10. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. (1989) The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab 68:632-637.
11. Goodman WK, Kozak MJ, Liebowitz M, White KL (1996) Treatment of obsessive compulsive disorder with fluvoxamine: A multicenter, double-blind, placebo controlled trial. Int Clin Psychopharmacol 11:21-29.
12. Jefferson JW (1995) Social phobia: A pharmacologic treatment overview. J Clin Psychiatry 56 (Suppl 5):18-24.
13. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ. (1993) Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications of therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3:13-21.
14. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995) Sertraline for social phobia: A double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368-1371.
15. Lepola U, Koponen H, Leinonen E (1994) Citalopram in the treatment of social phobia: A report of three cases. Pharmacopsychiatry 27:186-188.
16. Levin AP, Saoud JB, Strauman T. (1993) Responses of generalized and discrete social phobies during public speaking. J Anxiety Dis 7:207-221.
17. Liebowitz MR, Fyer AB, Gorman JM, Dillon D, Davies S, Stein JM, et al. (1985a) Specificity of lactate infusions in social phobia versus panic disorders. Am J Psychiatry 142:947-950.
18. Liebowitz MR, Gorman JM, Fyer AB, Klein DF. (1985b) Social phobia, review of a neglected anxiety disorder. Arch Gen Psychiatry 42:729-736.
19. Marks IM, Mathews AM (1979) Brief standard self-rating for phobic patients. Behav Res Ther 17:263-267.
20. Miner CM, Davidson JRT, Lotts NLS, Tupler LA, Charles HC, Krishnan KRR. (1995) Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 38:696-698.
21. Montelcone P, Catapano F, Tortorella A, Di Martino S, Maj M. (1995) Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. Psychoneuroendocrinology 20:763-770.
22. Naftolowitz DF, Vaughn BV, Ranc J, Tancer MF (1994) Response to alcohol in social phobia. Anxiety 1:96-99.
23. Potts NLS, Davidson JRT, Krishnan RR, Doraiswamy PM, Ritchie JC (1991) Levels of urinary free cortisol in social phobia. J Clin Psychiatry 52 (Suppl 11):41-42.
24. Reich J, Yates W (1988) A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 145:590-594.
25. Reist C, Helmeste D, Albers L, Chhay H, Tang SW. (1996) Serotonin indices and impulsivity in normal volunteers. Psychiatr Res 60:177-184.
26. Roberts JM, Wohlreich GM, Santos AB (1995) Sertraline in the treatment of social phobia. Am J Psychiatry 152:810-811.
27. Rowland NE, Carlton J (1986) Neurobiology of an anorectic drug: Fenfluramine. Prog Neurobiol 27:13-62.
28. Sheehan DV, Harnett-Sheehan K (1990) Psychometric assessment of anxiety disorders. In: Anxiety: Psychobiological and Clinical Perspectives (Sartorius N, Andreoli V, Cassano G, Eisenberg L, Kielhotz P, Pancheri P, Racagni G, eds). Washington, DC: Hemisphere Publishing Corporation, pp. 85-110.
29. Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95.
30. Spitzer RL, Williams JBW, Gibbon M (1987) Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research.
31. Stein MB, Siebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia: A randomized controlled trial. JAMA 280:708-13.
32. Sternbach H (1990) Fluoxetine treatment of social phobia. J Clin Psychopharmacol 10:230-231.
33. Strauss WL, Layton ME, Hayes CE, Dager SR (1997) 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 154:516-22.
34. Strauss WL, Layton ME, Dager SR (1998) Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155:380-384.
35. Uhde TW, Tancer ME, Gerlernter CS, Vittone BJ. (1994) Normal urinary free cortisol and postdexamethasone cortisol in social phobia: Comparison to normal volunteers. J Affect Dis 30:155-161.
36. Van Ameringen M, Mancini C, Streiner D (1994) Sertraline in social phobia. J Affect Dis 31:141-145.
37. Van Vliet IM, Den Boer JA, Westerberg HGM (1994) Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine. Psychopharmacology 115:128-134.